Probiotics for constipation and gut microbiota in Parkinson's disease

Du, Yitong; Li, Yue; Xu, Xiang; Li, Rongxue; Zhang, Mingkai; Cui, Ying; Zhang, Liyan; Wei, Zheng Zachory; Wang, Shiya; Tuo, Houzhen

doi:10.1016/j.parkreldis.2022.08.022

Cited by 39 publications

(40 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies [44,46] that followed up after 4 weeks showed no signi cant difference (SMD, -1.29; 95% CI, -2.76 to 0.18; I 2 = 94%; P = 0.09). Three studies [11,17,44] that followed up after 12 weeks showed no signi cant difference (SMD, -0.33; 95% CI, -1.91 to 1.24; I 2 = 96%; P = 0.68) (Fig. 3C).…”

Section: Effects Of Probiotics On Gastrointestinal Symptomsmentioning

confidence: 94%

“…Two studies [22,30] that followed up after 8 weeks showed signi cant improvement in the probiotics groups (SMD, 0.73; 95% CI, 0.35 to 1.10; I 2 = 23%; P < 0.001). Two studies [11,44] that followed up after 12 weeks showed signi cant improvement in the probiotics groups (SMD, 1.11; 95% CI, 0.73 to 1.49; I 2 = 0%; P < 0.001) (Fig. 3A).…”

Section: Effects Of Probiotics On Gastrointestinal Symptomsmentioning

confidence: 95%

“…All ten studies were randomized trials, and a majority of them (n = 6) described the randomization method. However, only the abstract was available for two [30,49] studies, which did not provide su cient information, while another studies [11,17] did not su ciently explain the allocation concealment method.…”

Section: Risk Of Bias Assessment and Assessment Of Publication Biasmentioning

confidence: 99%

“…Symptoms of constipation were reported in four studies [11,17,44,46] that included seven comparisons. There were no signi cant differences in the summary effect size between the groups (SMD, -0.62; 95%CI, -1.70 to 0.45; I 2 = 95%; P = 0.25).…”

Section: Effects Of Probiotics On Gastrointestinal Symptomsmentioning

confidence: 99%

“…Quality of life were reported in ve studies [11,22,44,46,49] that included six comparisons. There were signi cant improvement in the probiotics groups (SMD, -1.13; 95%CI, -1.86 to -0.40; I 2 = 92%; P = 0.002).…”

Section: Effects Of Probiotics On Pd Scalementioning

confidence: 99%

See 4 more Smart Citations

Effects of probiotic supplementation on gastrointestinal motility, inflammation, motor and non-motor symptoms in Parkinson's disease: a meta-analysis of randomized controlled trials

Park

Lee

Ham

et al. 2023

Preprint

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disease. It is believed that “gut dysbiosis” can cause PD; therefore, whether probiotics can be used as adjuvants in the treatment of PD is being actively investigated. We performed a systematic review and meta-analysis to evaluate the effectiveness of probiotic therapy in PD patients. PUBMED/MEDLINE, EMBASE, Cochrane, Scopus, PsycINFO and Web of Science databases were searched till January 9, 2023. The meta-analysis used a random effects model and the effect size was calculated as mean difference or standardized mean difference. Ten studies with 760 participants were included in the final analysis. The meta-analysis revealed a significant improvement in gastrointestinal motility (standardized mean difference [95% confidence interval]) (0.78 [0.57-0.98]) and antioxidant capacity (1.73 [0.26 to 3.21]). Serum inflammatory markers (-8.64 [-16.05 to -1.23]), diabetes risk (-3.41 [-4.65 to -2.17]), Unified PD Rating Scale Part III (-4.12 [-7.81 to -0.43]), non-motor symptom (-5.55 [-8.30 to -2.80]), quality of life (-1.13 [-1.86 to -0.40]), anxiety scale (-2.21 [-3.41 to -1.00]) and depression scale (-1.53 [-1.99 to -1.07]) demonstrated a significant decrease. The Bristol stool scale, constipation and risk of dyslipidemia were not significantly improved. In a subgroup analysis, capsules further improved gastrointestinal motility than fermented milk. This review found that probiotic supplements may be suitable for increasing gastrointestinal motility, reducing inflammation, and improving motor and non-motor symptoms of PD. Further research is warranted to determine the mechanism of action of probiotics and the optimal treatment protocol.

show abstract

Section: Effects Of Probiotics On Gastrointestinal Symptomsmentioning

confidence: 94%

Section: Effects Of Probiotics On Gastrointestinal Symptomsmentioning

confidence: 95%

Section: Risk Of Bias Assessment and Assessment Of Publication Biasmentioning

confidence: 99%

Section: Effects Of Probiotics On Gastrointestinal Symptomsmentioning

confidence: 99%

Section: Effects Of Probiotics On Pd Scalementioning

confidence: 99%

See 3 more Smart Citations

Effects of probiotic supplementation on gastrointestinal motility, inflammation, motor and non-motor symptoms in Parkinson's disease: a meta-analysis of randomized controlled trials

Park

Lee

Ham

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Time‐Resolved Evaluation of L‐Dopa Metabolism in Bacteria‐Host Symbiotic System and the Effect on Parkinson's Molecular Pathology

Kim,

Nguyen,

Moon

et al. 2024

Small Methods

View full text Add to dashboard Cite

The gut microbiome influences drug metabolism and therapeutic efficacy. Still, the lack of a general label‐free approach for monitoring bacterial or host metabolic contribution hampers deeper insights. Here, a 2D nuclear magnetic resonance (NMR) approach is introduced that enables real‐time monitoring of the metabolism of Levodopa (L‐dopa), an anti‐Parkinson drug, in both live bacteria and bacteria‐host (Caenorhabditis elegans) symbiotic systems. The quantitative method reveals that discrete Enterococcus faecalis substrains produce different amounts of dopamine in live hosts, even though they are a single species and all have the Tyrosine decarboxylase (TyrDC) gene involved in L‐dopa metabolism. The differential bacterial metabolic activity correlates with differing Parkinson's molecular pathology concerning alpha‐synuclein aggregation as well as behavioral phenotypes. The gene's existence or expression is not an indicator of metabolic activity is also shown, underscoring the significance of quantitative metabolic estimation in vivo. This simple approach is widely adaptable to any chemical drug to elucidate pharmacomicrobiomic relationships and may help rapidly screen bacterial metabolic effects in drug development.

show abstract